Innovative therapies for ovarian cancer, including engineered T cells and antibody-drug conjugates, show promise in improving patient outcomes.
Video content is prompted by the following: Future Potential of Novel Therapeutic Approaches
Key Discussion Points:
Notable Insights:
“CAR T, the limitation with ovary is that a lot of our proteins are intracellular proteins...but CAR-NK may be a completely different ballgame for us.”
“The challenge with [cellular therapies] is...you can’t leave people just sitting around for 2 months waiting for manufacture of cells who have kind of actively growing disease. It’s not ethical.”
Using AI, Socioeconomic Factors to Predict Outcomes After Allo-SCT for AML
August 16th 2025Artificial intelligence (AI) and socioeconomic factors enhance risk stratification for patients with acute myeloid leukemia (AML) post transplant, aiming to reduce hospital readmissions and disease progression.
Read More